ISSN: 1300-7777 E-ISSN: 1308-5263
Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib [Turk J Hematol]
Turk J Hematol. 2011; 28(3): 232-234 | DOI: 10.5152/tjh.2011.60  

Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib

Semra Paydaş1, Berna Bozkurt Duman1, Melek Ergin2
1Department Of Oncology, Faculty Of Medicine, Çukurova University, Adana, Turkey
2Department Of Pathology, Faculty Of Medicine, Çukurova University, Adana, Turkey

Imatinib is an important example of tyrosine kinase inhibitors (TKIs) used in clinical practice. Imatinib blocks the ATP binding site of the Bcr-Abl fusion protein and selectively inhibits Bcr-Abl tyrosine kinase (TK) activity. Treatment of chronic myelocytic leukemia (CML) with imatinib is encouraging and it has an acceptable toxicity profile, and as such has changed the management of CML during the last decade. As with all drugs used in clinical practice, side effects of imatinib have been reported in studies with extended follow-up periods. In addition, some neoplastic disorders have been reported to occur during imatinib therapy. Herein we present a CML case that developed non-Hodgkin’s lymphoma (NHL) while receiving imatinib treatment.

Keywords: Imatinib, chronic myelocytic leukemia, non-Hodgkin’s lymphoma


İmatinib alan bir kronik miyeloid lösemi olgusunda gelişen non-Hodgkin lenfoma

Semra Paydaş1, Berna Bozkurt Duman1, Melek Ergin2
1Çukurova Üniversitesi Tıp Fakültesi Onkoloji Bilim Dalı, Adana
2Çukurova Üniversitesi Tıp Fakültesi Patoloji Ana Bilim Dalı, Adana

İmatinib klinikte kullanılan tirozin kinaz (TK) inhibitörlerinin önemli bir örneğidir. Bcr Abl füzyon proteininin ATP bağlayan bölgesini bloke eder ve selektif olarak TK aktivitesini bloke eder. Kronik miyeloid lösemide (KML) imatinib'e yanıt heyecan vericidir ve kabul edilebilir toksisite profiline sahiptir. Bu özellikleri ile son on yılda KML yönetimini değiştirmiştir. Klinikte kullanılan her ilaçta olduğu gibi bazı yan etkiler uzun süreli takipte rapor edilmektedir. Diğer yan etkilerine ek olarak, imatinib tedavisi sırasında bazı neoplastik bozukluklar yayımlanmıştır. Burada KML nedeniyle imatinib almakta iken non-Hodgkin lenfoma (NHL) gelişen bir olgu sunulmuştur.

Anahtar Kelimeler: İmatinib, kronik miyeloid lösemi, non-Hodgkin lenfoma


Semra Paydaş, Berna Bozkurt Duman, Melek Ergin. Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib. Turk J Hematol. 2011; 28(3): 232-234

Corresponding Author: Semra Paydaş, Türkiye


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar


 



Impact Factor (2016) = 0.686